Multiply Labs Raises $75 Million Series B Led by Patrick Soon-Shiong

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant have entered into a collaboration to support production of the company's experimental cancer vaccine DCVax-L. NHSBT's Therapeutic Apheresis Services is carrying out leukapheresis procedures to collect the immune cell starting material needed for the DCVax-L treatment, while its Cellular and Molecular Therapies team is providing specialist cell processing and handling of cellular material, working with Northwest Biotherapeutics and Advent Bioservices. The collaboration initially involves Leeds and Oxford, and the parties are exploring phased expansion of the model to additional NHSBT locations across England. Northwest Biotherapeutics CEO Linda Powers said NHSBT's capabilities can significantly enhance the scale-up and accessibility of DCVax-L, and NHSBT Medical Director Dr James Griffin said the aim is to help make cutting edge advanced therapies more accessible. DCVax-L is a treatment for Glioblastoma multiforme, an aggressive form of primary brain cancer, as well as all solid tumours, and Northwest Biotherapeutics has submitted a Marketing Authorisation Application for commercial approval in the UK that is currently undergoing review.

Johnson & Johnson is expected to report quarterly earnings of $2.66 per share in its forthcoming report, a decline of 5% year over year, on revenues projected to reach $25.37 billion, up 5.8% from the same quarter last year. Over the last 30 days, the consensus EPS estimate for the quarter has been revised downward by 0.3%. Within the company's Innovative Medicine segment, analysts project worldwide sales of $16.59 billion, up 6.6%, including $708.49 million for CARVYKTI, up 35.2%, and $612.16 million for SPRAVATO, up 33.4%. In MedTech, the consensus estimate for worldwide Orthopaedics Trauma sales stands at $831.48 million, up 4.9%, while worldwide Orthopaedics Spine, Sports & Other is projected at $700.77 million, up 0.4%, and worldwide Surgery Advanced at $1.17 billion, up 0.7%. International sales are expected to reach $10.77 billion, up 4.7%, and organic sales growth is projected at 6.8% versus 5.4% a year ago.

The fair value estimate for Iovance Biotherapeutics has been raised to US$12.80 per share from US$10.00, according to Simply Wall St. The revision reflects stronger expectations for the Amtagvi launch, margin trends and upcoming data, with the revenue growth assumption shifting from 43.38% to 45.57% and the net profit margin assumption moving from 9.50% to 12.09%. H.C. Wainwright lifted its price target to US$20 from US$9, citing FY26 total revenue guidance of US$410m to US$420m tied to U.S. demand for Amtagvi and Proleukin, while Wells Fargo moved to US$18 from US$14 and Goldman Sachs pointed to an inflection in the Amtagvi launch and easing logistical challenges. Barclays flagged durability in second line lung cancer for lifileucel ahead of IOV-LUN-202 data, while UBS, which raised its target to US$7 from US$4 and remains Neutral, noted that a strong Amtagvi quarter and gross margin of 56% came alongside a 74% rally in the stock. The valuation model's future P/E multiple changed from 75.55x to 72.80x and the discount rate moved from 7.47% to 7.50%.

The global cell and gene therapy biomanufacturing market is projected to grow from $12.35 billion in 2025 to $13.83 billion in 2026, a compound annual growth rate of 12%, and to reach $21.46 billion by 2030 at a compound annual growth rate of 11.6% from 2026, according to the Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026 added to ResearchAndMarkets.com. Growth is being driven by the increasing commercialization of cell and gene therapies, demand for scalable viral vector production, wider adoption of personalized medicine, and expansion among contract development and manufacturing organizations, alongside automation, digitalization, and investment in modern biomanufacturing facilities. The report cites the American Society of Gene and Cell Therapy's finding that the number of gene therapies in Phase III development increased by 10% during the fourth quarter of 2023 compared with the previous quarter, the first quarterly increase since the third quarter of 2022. In May 2026, Andelyn Biosciences launched its LVV Curator platform to streamline lentiviral vector manufacturing, using a modular, prevalidated framework based on Curator methodology previously applied across more than 100 adeno-associated virus programs. In January 2024, Oxford Biomedica plc acquired ABL Europe SAS for $17.35 million, expanding its manufacturing presence in Europe and its viral vector development and production services. North America was the largest cell and gene therapy biomanufacturing market in 2025, while Asia-Pacific is forecast to be the fastest-growing region; companies featured include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, and Samsung Biologics Co. Ltd.